Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H17N3O4S |
| Molecular Weight | 395.432 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)C2=C(C=CC=C2)N=C1COC3=CC=C(C[C@@H]4SC(=O)NC4=O)C=C3
InChI
InChIKey=IETKPTYAGKZLKY-INIZCTEOSA-N
InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)/t16-/m0/s1
| Molecular Formula | C20H17N3O4S |
| Molecular Weight | 395.432 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Balaglitazone, also known as DRF-2593; NNC-61-0645; NNC-61-2344; NN-2344; NNC-610645; NNC-612344, is an agonist of peroxisome proliferator-activated receptor (PPAR)γ. Balaglitazone plays an important role in the regulation of insulin, triglycerides and lipid metabolism. It is an attractive target for the therapy of Type II Diabetes. Balaglitazone is a partial agonist of PPARγ. It has showed potent effects on lowering blood glucose in various animal models. Balaglitazone passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone. Balaglitazone exists as two enantiomers: BALAGLITAZONE, (S)- and BALAGLITAZONE, (R)-. A capillary electrophoresis method for separation of a racemic mixture of glitazone compounds has being used. The method separated the R and S enantiomers of balaglitazone, and showed that the samples contained an equal (50:50) quantity of the enantiomers as a mixture. The Rs for the separations were 3.5 for balaglitazone enantiomers.
Originator
Approval Year
Sample Use Guides
One arm balaglitazone 10mg, one arm balaglitazone 20mg, orally taken once daily.
Route of Administration:
Oral
In a cell-based assay using HEK293 cells transfected with fused PPARγ, treatment of balaglitazone showed sigmoid activation with an EC50 value of 1.35uM. When combined with rosiglitazone, balaglitazone at increased concentrations resulted in the reduction of rosiglitazone’s activity to the level of balaglitazone alone at concentration of 100 nM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:26:32 GMT 2025
by
admin
on
Mon Mar 31 22:26:32 GMT 2025
|
| Record UNII |
KPK1FF8WC4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
KPK1FF8WC4
Created by
admin on Mon Mar 31 22:26:32 GMT 2025 , Edited by admin on Mon Mar 31 22:26:32 GMT 2025
|
PRIMARY | |||
|
76968727
Created by
admin on Mon Mar 31 22:26:32 GMT 2025 , Edited by admin on Mon Mar 31 22:26:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
